KINGDOM OF BELGIUM

FEDERAL AGENCY FOR MEDICINES AND HEALTH PRODUCTS

Royal Decree laying down the conditions for prescribing and dispensing medicinal products belonging to GLP-1 analogues authorised with the indication of type 2 diabetes mellitus

PHILIPPE, King of the Belgians,

To all those present and those to come,
Greetings.

Having regard to the Law of 25 March 1964 on medicinal products for human use, Article 3, § 2, subparagraph 1, inserted by the Law of 1 May 2006 and amended by the Law of 5 May 2022, and Article 7, as last amended by the Law of 18 May 2022;

Having regard to the Law of 22 April 2019 on the quality of healthcare practice, Article 30, subparagraph 1, amended by the Law of 11 July 2023;
Having regard to the Royal Decree of 9 November 2023 laying down the conditions for prescribing and dispensing medicinal products belonging to GLP-1 analogues authorised with the indication of type 2 diabetes mellitus;
Having regard to the opinion of the Finance Inspector given on ...;

Having regard to the opinion xxxx/x of the Council of State, given on (date), pursuant to Article 84, § 1, subparagraph 1(2), of the laws on the Council of State, consolidated on 12 January 1973;

On the proposal of the Minister for Public Health,

I HAVE DECREED AND HEREBY DECREE:

Article 1. In Article 3 of the Royal Decree of 9 November 2023 laying down the conditions for prescribing and dispensing medicinal products belonging to GLP-1 analogues authorised with the indication of type 2 diabetes mellitus, the words ‘31 August 2024’ are replaced by the words ‘31 December 2024’.

Article 2. This Decree shall enter into force on

the day following its publication in the Moniteur belge [Belgian Official Gazette].
Article 3. The Minister for Public Health shall be responsible for the implementation of this Decree.

Issued , on

By the King:

The Minister for Public Health,

Frank VANDENBROUCKE